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Abstract The utility of performing blood cultures in patients
with a suspected skin infection is debated. We investigated the
association between blood culture positivity rates and
patients’ clinical condition, including acute disease severity
and comorbidity.We performed a retrospective study, including
patients with cellulitis and wound infection who had been
enrolled in three Dutch multicenter studies between 2011 and
2015. Patients’ acute clinical condition was assessed using the
Modified Early Warning Score (MEWS; severe: MEWS ≥2)
and comorbidity with the Charlson Comorbidity Index (CCI;
severe: CCI ≥2). A total of 334 patients with a suspected skin
infection were included. Blood cultures were performed in 175
patients (52%), 28 of whom (16%) had a positive blood culture.
Data on the clinical condition were collected in 275 patients.
Blood cultures were performed in 76% of the patients with a
severe acute condition, compared with 48% with a non-severe
acute condition (OR 3.5; 95% confidence interval: 2.0–6.2;
p < 0.001). Blood cultures were positive in 18% and 12%
respectively (OR 1.7 (0.7–4.1); p = 0.3). Blood cultures were
performed in 53% of patients with severe comorbidity,
compared with 61% without severe comorbidity (OR 0.7;
0.4–1.2; p = 0.2). Blood cultures were positive in 25% and
10% respectively (OR = 3.1; 1.2–7.5; p = 0.02). The blood
culture positivity rate among hospitalized patients diagnosed
with skin infections was higher than the rates reported by the
Infectious Diseases Society of America guidelines, particularly
in patients with severe comorbidity. Therefore, the recommen-
dations concerning blood culture performance in patients with a
skin infection should be reconsidered.
Introduction
Acute bacterial skin and soft-tissue infections (SSTI) are among
the most common indications for antibiotic use in hospitalized
adults [1]. Cellulitis involves the deep dermis and subcutaneous
tissues, whereas erysipelas is limited to superficial dermal struc-
tures with well-defined borders, although it is presently consid-
ered a manifestation of cellulitis [2–5]. Most of these infections
arise from beta-hemolytic streptococci. Staphylococcus aureus
can cause cellulitis, typically in the presence of an open wound
or previous penetrating trauma. Several other organisms can
also cause cellulitis, but usually only in special circumstances
[2]. Wound infections are defined by the presence of a pre-
existing skin lesions at the time of skin infection onset, such
as a chronic ulcer or a trauma-related skin lesion, and can vary
from superficial skin infection to deeper infection with involve-
ment of tissues under the skin [6, 7].
The current Infectious Diseases Society of America
(IDSA) guidelines do not recommend routine performance
of blood cultures in patients with cellulitis and erysipelas
[2]. Previous studies reported low positivity rates (4–13%)
and marginal consequences for treatment, as standard empir-
ical therapy covers most causative pathogens, including beta-
hemolytic streptococci [2, 3, 8–11].
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Although S. aureus and gram-negative bacteria are less
frequently noted to cause SSTI, they require different treat-
ment [2, 9]. As these pathogens are more frequently found in
specific patient groups, IDSA guidelines recommend
performing blood cultures only in patients with malignancy,
chemotherapy, neutropenia, severe cell-mediated immunode-
ficiency, immersion injuries, and animal bites [2]. These rec-
ommendations, however, are based on little evidence and do
not take the patients’ acute clinical condition into account.
The aim of our study was to investigate the association
between blood culture positivity rates and the patient’s clinical
condition, including acute disease severity and comorbidity.
Materials and methods
Study setting and population
We performed a retrospective study in the databases of two
multicenter observational studies (RIANT and IMPACT) and
one multicenter intervention study (AB checklist), performed
between 2011 and 2015 in 40 university and non-university
hospitals in the Netherlands (http://www.trialregister.nl; NTR
5933) [12, 13]. The RIANT study developed and validated a
set of generic quality indicators to define and measure the
appropriateness of antibiotic use in the treatment of bacterial
infections in hospitalized adult patients. The IMPACT study
compares different methods, including a point prevalence
survey using these validated quality indicators, to measure
the appropriateness of antibacterial use in hospitalized adult
patients. The AB checklist study implemented an antibiotic
checklist based on these validated quality indicators and
evaluated the effect of checklist use on the length of hospital
stay and appropriate antibiotic use. Inclusion criteria for all
three studies were: adult patients (≥18 years old) admitted to
an acute care department with a suspected bacterial infection
and treated with antibiotics (ATC group J01) for at least
24 hours. In all three studies, patients were excluded if
antibiotics were used as prophylaxis, or when antibiotic
treatment was started on the ICU department or in another
hospital. All patients were randomly selected. For the
present study, we identified the patients with cellulitis in
these databases, including those with a clinical diagnosis of
erysipelas; we also included patients with a wound infection.
Assessments
Data were collected from electronic medical records and med-
ication charts. In all three studies, data were recorded on pa-
tient characteristics, including sex, age and diagnosis, and
whether blood culture had been performed, including the
number of cultures and their results.
In two studies, RIANT and AB checklist, additional data
were recorded on the acute clinical condition and comorbidity
[12, 13]. Patients’ acute clinical condition was assessed at the
start of treatment using the Modified Early Warning Score
(MEWS) [14]. A severe acute condition was defined by
MEWS ≥2, non-severe acute condition by MEWS <2.
Comorbidity was assessed using the Charlson Comorbidity
Index (CCI) [15] and severe comorbidity was defined by
CCI ≥2.
Analysis
Numbers of blood cultures taken and numbers of positive
cultures, including type of pathogen, were combined for all
three studies and expressed in absolute numbers and percent-
ages. We compared the proportions of positive blood cultures
between patients diagnosed with cellulitis, those with a clini-
cal diagnosis of erysipelas, and those with a wound
infection. In the evaluation of the association between blood
culture positivity rates and patients’ clinical condition we only
included patients of the RIANT and AB checklist studies
[12, 13]. We compared the proportions of patients with a
blood culture taken and positivity rates between patients with
a severe and those with a non-severe acute clinical condition,
and between patients with and without severe comorbidity.
Additionally, we performed a sub-analysis in which we com-
pared patients with or without diabetes mellitus. We used Chi-
squared tests to compare proportions. As age and comorbidity
are often correlated, we performed a multivariate logistic re-
gression analysis to investigate the association between the
positivity rate of blood cultures and acute clinical condition,
comorbidity and age of the patient. P < 0.05 was considered
statistically significant. Analyses were carried out using IBM
SPSS Statistics, version 23.0.
Results
A total of 334 patients with a suspected SSTI were included in
our study, of whom 258 (77%) were diagnosed with cellulitis
and 76 (23%) with a wound infection. Blood cultures were
performed in 175 out of 334 patients (52%): in 153 out of 258
patients (59%) with cellulitis and in 22 out of 76 patients
(29%) with a wound infection. Twenty-eight out of 175 pa-
tients (16%) had a positive blood culture: 23 out of 153 pa-
tients (15%) with cellulitis and 5 out of 22 with a wound
infection (23%). One hundred and nine of the patients with
cellulitis (42%) had a clinical diagnosis of erysipelas. Blood
cultures were performed in 70 out of 109 patients (64%) with
erysipelas and 8 out of 70 (11%) had a positive blood culture.
Table 1 presents the baseline characteristics of all patients, of
patients in whom blood cultures were performed, and of pa-
tients with positive blood cultures.
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No significant difference was found in positivity rates be-
tween the patients with a diagnosis of cellulitis not classified
as erysipelas (n = 83) and those with a clinical diagnosis of
erysipelas (n = 70; OR 0.6; 95% confidence interval: 0.2–1.5;
p = 0.3), or between patients with cellulitis (n = 153) and those
with a wound infection (OR 0.6; 0.2–1.8; p = 0.4).
Twenty-nine pathogens were identified. Most cultured
species were Streptococcus species (in 12 cultures), Gram-
negative bacteria (in 8 cultures), and Staphylococcus aureus
(in 7 cultures). See Table 2 for details per diagnosis.
Data on acute clinical condition and comorbidity were re-
corded in 275 patients, of whom 214 (78%) were diagnosed
with cellulitis and 61 (22%) with a wound infection. Eighty-
five out of 275 (31%) had a severe acute clinical condition,
102 out of 275 (37%) had severe comorbidity. Table 3 pre-
sents the baseline characteristics of these patients. Blood cul-
tures were performed in 76% of the patients with a severe
acute clinical condition, compared with 48% of patients with
a non-severe condition (OR 3.5; 1.9–6.2; p < 0.001). Blood
cultures were positive in 18% and 12% respectively (OR 1.7;
0.7–4.1; p = 0.3). In 53% of the patients with a severe comor-
bidity blood cultures were performed, compared with 61% of
patients without a severe comorbidity (OR =0.7; 0.4–1.2;
p = 0.2). Blood cultures were positive in 25% and 10% re-
spectively (OR = 3.1; 1.2–7.5; p = 0.02; Table 4).
Of the 275 patients included in the comorbidity analysis, 73
were diagnosed with diabetes mellitus. Blood cultures were
performed in 44 of these patients. Blood cultures were positive
in 9 out of 44 of the patients with diabetes (20%), compared
with 14 out of 113 (13%) of the patients without diabetes (OR
1.8; 0.7–4.6; p = 0.2).
Themean age of patients with severe comorbidity was higher
than the mean age of patients without severe comorbidity
(Table 4). A higher age was significantly associated with posi-
tive blood cultures (OR = 1.03; 1.0–1.06; p = 0.07). In the
multivariate regression analysis, the severity of comorbidity
was a stronger predictor of positive blood cultures than age
(CCI: OR 2.3; 0.9–6.2; p = 0.09, compared with age: OR 1.0;
1.0–1.1; p = 0.3).
Discussion
In this study, we found that blood cultures were taken in 52%
of patients hospitalized with cellulitis or wound infections,
with a positivity rate of 16%. Significantly more blood cul-
tures were performed in patients with a severe compared with
patients with a non-severe acute clinical condition, but posi-
tivity rates of blood cultures were significantly higher in pa-
tients with severe comorbidity.
The positivity rate in our study was higher than in previous
studies, where blood cultures were found to be positive in 4–
9% of patients with cellulitis or erysipelas [2, 8, 9, 11]. In one
study, higher positivity rates were found for purulent com-
pared with nonpurulent infections [7]. Definitions and inclu-
sion criteria differed between studies, which may explain the
range in positivity rates.
Our study supports previous findings stating that Streptococci
species are the most frequently cultured species in patients with
cellulitis and erysipelas, followed by S. aureus and Gram-
negative bacteria [9]. S. aureuswas cultured in 3 of the 5 patients
with a wound infection and a positive blood culture, in line with
the literature describing that this pathogen is typically found in
patients with an open wound or previous penetrating trauma [2].
Remarkably, in 4 out of 8 patients with a clinical diagnosis of
Table 1 Baseline characteristics
of patients with a suspected skin
and soft-tissue infection (SSTI)
Characteristicsa All patients Patients in whom blood
cultures were performed
Patients with positive
blood cultures
n = 334 n = 175 n = 28
Sex, male 181 (55) 96 (55) 15 (54)
Age, mean (SD) 66.0 (17) 65.1 (16) 69.7(16)
Hospital
University 42 (13) 17 (10) 3 (11)
Non-university 292 (87) 158 (90) 25 (89)
Diagnosis
Cellulitis 258 (77) 153 (87) 23 (82)
Erysipelas subgroup 109 (33) 70 (40) 8 (29)
Wound infection 76 (23) 22 (13) 5 (18)
Antibiotics
Started intravenously (IV) 312 (93) 172 (98) 28 (100)
Started orally (O) 22 (7) 3 (2) 0 (0)
Total 334 (100) 175 (100) 28 (100)
a Numbers are n (%), unless otherwise indicated
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erysipelas and a positive culture, Gram-negative bacteria were
cultured.
Clinicians were more likely to perform blood cultures in
patients with a severe acute clinical condition, defined by a
MEWS ≥2. A recent Swedish study described a similar asso-
ciation, showing that blood cultures were more frequently
performed in patients who fulfilled the severe inflammatory
response syndrome (SIRS) criteria [8]. However, they did not
compare the positivity rates of blood cultures between patients
who did or did not fulfill the SIRS criteria. An American
retrospective chart review did look at positivity rates and acute
clinical condition: they compared—among others—positivity
rates of blood cultures in patients with cellulitis with or without
fever [11]. Unexpectedly, patients without fever had positive
blood cultures significantly more frequently than patients with
fever, which supports our findings that a severe acute clinical
condition is not associated with a higher positivity rate.
In our study clinicians were not more likely to perform
blood cultures in patients with severe comorbidity, defined
by a CCI ≥2, but the positivity rate was significantly higher
in these patients. An association between comorbidity and
positivity rates has been described before, especially for ma-
lignancy, immunodeficiency or diabetes mellitus [2, 10].
Diabetes mellitus is a comorbidity with a high prevalence
and often contributes to the total CCI score. A relationship
between diabetes mellitus and positive blood cultures has
been described [16]. In our study, the positivity rate for pa-
tients with diabetes was also higher than in patients without
diabetes, but this difference was not statistically significant.
As age is the most important risk factor for the presence of
comorbidities, an association between the patient’s age and
the positivity rate of blood cultures is plausible. The multivar-
iate regression analysis illustrated, however, that comorbidity
is a better predictor of blood culture positivity.
Table 2 Microbiology results of
patients with a suspected SSTI
and a positive blood culture
Pathogen Total number
of pathogensa
Number of pathogens per diagnosisa
Cellulitis Wound infection
Erysipelas subgroup
Negative culture results
No pathogen 140 (96) 125 59 15
Contamination 6 (4) 5 3 1
Total 146 (100) 130 62 16
Positive culture results
Staphylococcus species
S. aureus 7 (24) 4 3
S. capitis 1 (3) 1 1
Streptococcus species
S. pneumoniae 1 (3) 1
S. pyogenes 3 (10) 3 1
S. dysgalactiae 2 (7) 2 1
S. salivarius 1 (3) 1
Group A 1 (3) 1
Group B 2 (7) 2
Group C 1 (3) 1
Group G 1 (3) 1 1
Enterococcus species
E. faecium 1 (3) 1
Gram-negative bacteria
E. coli 1 (3) 1
K. oxytoca 2 (7) 2 1
P. aeruginosa 3 (10) 3 1
Pseudomonas species 1 (3) 1 1
H. influenza 1 (3) 1 1
Total 29b (100) 24 8 5
aNumbers are n (%), unless otherwise indicated
b In one patient two pathogens were identified
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Our study has several strengths. We provide recent data on
blood culture positivity rates in patients hospitalized with an
SSTI, which is necessary as the IDSA guidelines still report
positivity rates ≤5% based on a study from 1999 [10]. Our
study is large and representative, as we included patients from
nearly half of all Dutch hospitals, including university, teach-
ing, and general hospitals.
Our study has limitations. As it was based on retrospective
chart reviews, it was the clinicians’ decision as regards which
patients’ blood cultures were performed. Our data clearly show
that clinicians are more inclined to perform blood cultures in
severely ill patients. However, we also showed that positivity
rates were better predicted by comorbidity. Furthermore, be-
cause of this retrospective setup, we selected patients based
on the diagnosis documented in the patient files and we were
dependent on the documentation of health care providers.
In conclusion, the blood culture positivity rate among hos-
pitalized patients diagnosed with SSTIs was higher than the
rates reported by the IDSA guidelines, particularly in patients
with severe comorbidity. Therefore, the recommendations
concerning blood culture performance in patients with an
SSTI should be reconsidered.
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